external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus.
Explore the latest updates from the life science industry.

BIOTECH

Magnetic Bead Separation: More Than Just a Magnet

We sit down with Sepmag's Lluís M. Martinez, Founder & CSO, and Josep-Maria Simó, Managing Director, to discuss the current state and future of magnetic separation technology.

Featured Articles.

BIOTECH

Cerevance Reports Phase 2 Results for Solengepras in Early-Stage Parkinson’s Disease

BIOTECH

Immunocore Unveils Promising HIV Functional Cure Data at CROI 2025

HEALTH

Training the Immune System to Outlast Cancer

PHARMA

Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal

PHARMA

The Current and Future State of Personalised Medicine

PHARMA

Novo Nordisk Announces Promising Results for CagriSema but Stocks Tell Different Story

BIOPROCESSING

Navigating the Digitalisation Journey in the Biopharmaceutical Industry

SUSTAINABILITY

A Modern-Day Noah's Ark?

BIOTECH

Asimov and Revopsis Therapeutics Enter Strategic Licensing Agreement to Advance Gene Therapy Solutions

Latest News.

27th April, 2025

01. VYNE Therapeutics Faces Clinical Hold on VYN202 Program Following Toxicity Findings

VYNE Therapeutics has paused its Phase 1b trial of VYN202 for psoriasis after the FDA imposed a clinical hold due to testicular toxicity observed in non-clinical studies, though no serious adverse events were reported in patients.

23rd April, 2025

02. Ascletis Enters the Obesity Drug Spotlight with Bold Play on Oral GLP-1 Candidate

Ascletis advances oral GLP-1 drug ASC30 after Phase 1b shows strong weight loss and safety, shifting focus to obesity with a slower dose-escalation strategy.

14th April, 2025

03. Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal

Pfizer halts once-daily oral GLP-1 program danuglipron after liver safety concerns, shifting focus to alternative obesity targets including a GIPR antagonist in Phase 2.

8th April, 2025

04. Kandu Health and Neurolutions Merge to Transform Stroke Recovery

Kandu, Inc. merges Kandu Health and Neurolutions to create an innovative, integrated approach to stroke recovery, combining advanced technology with personalized, at-home care.